For patients with elevated intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT)

ZIOPTAN provided powerful IOP reductions

Based on clinical studies of up to 24 months in 905 patients with a baseline pressure of 23–26 mmHg.  

ZIOPTAN is indicated for reducing elevated IOP in patients with OAG or OHT.


In clinical trials of patients receiving either preservative-containing or preservative-free ZIOPTAN, the most common pooled adverse reaction observed was conjunctival hyperemia, which was reported in a range of 4% to 20% of patients.

There are no adequate and well-controlled studies in pregnant women. ZIOPTAN should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus.

It is not known whether ZIOPTAN or the metabolites of ZIOPTAN are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when ZIOPTAN is administered to a nursing woman.

Use in pediatric patients is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use.

Before prescribing ZIOPTAN, please read the Prescribing Information.